story of the week
Abemaciclib Plus Endocrine Therapy for Adjuvant Treatment of HR+, HER2−, Node+, High-Risk, Early Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
J. Clin. Oncol 2020 Sep 20;[EPub Ahead of Print], SRD Johnston, N Harbeck, R Hegg, M Toi, M Martin, ZM Shao, QY Zhang, JL Martinez Rodriguez, M Campone, E Hamilton, J Sohn, V Guarneri, M Okada, F Boyle, P Neven, J Cortés, J Huober, A Wardley, SM Tolaney, I Cicin, IC Smith, M Frenzel, D Headley, R Wei, B San Antonio, M Hulstijn, J Cox, J O'Shaughnessy, P RastogiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.